Traduction de «report the results treatment » (Anglais → Français) :

reporting of the results of treatment | treatment results reporting | report the results of treatment | reporting treatment results

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include self-report data, analysis of blood and other body fluids, characteristic physical and psychological symptom ...[+++]s, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

Getting Government Right: Improving Results Measurement and Accountability: Annual Report to Parliament by the President of the Treasury Board [ Getting Government Right: Improving Results Measurement and Accountability ]

An extremely rare mitochondrial respiratory chain disease resulting in a neurodegenerative disorder with characteristics of psychomotor delay, hypotonia, areflexia, muscle weakness and wasting in the two patients reported to date. Combined oxidative

An extremely rare neurological disorder presumed to result from maldevelopment of the facial nucleus and/or cranial nerve reported in fewer than 10 families to date. It manifests as non-progressive, isolated, unilateral or bilateral, symmetrical or a

The combination of a propensity for venous thrombosis and seizures has been reported in two unrelated kindreds. Transmission is autosomal recessive. It results from a point mutation of PIGM, which reduces transcription of PIGM and blocks mannosylatio

Commissioner's Report: Results of the Public Review on the Effects of Potential Oil and Gas Exploration Offshore Cape Breton

Final report on the results of the public consultations on the future of the Central Experimental Farm, Ottawa

residues resulting from the treatment of fatty substances or animal or vegetable waxes

(Return tabled) Question No. 447 Ms. Kirsty Duncan: — With regard to diagnosis, treatment, awareness and prevention, and research of eating disorders: (a) do the Canadian Institutes of Health Research (CIHR) and Health Canada (HC) have any statistics about how many Canadians suffer from each of the following conditions, (i) anorexia nervosa, (ii) bulimia nervosa, (iii) binge eating disorder; (b) do the CIHR and HC have any statistics about the average costs of each of (i) anorexia nervosa, (ii) bulimia nervosa, (iii) binge eating disorder to the health system; (c) do the CIHR and HC have any statistics about how many Canadians (i) reco ...[+++]ver, (ii) relapse, (iii) die each year as a result of eating disorders; (d) do the CIHR and HC have any statistics about what treatment is available for eating disorders, broken down by province and territory, from (i) daily care to long-term residential care, (ii) how many publicly funded beds are available; (e) do the CIHR and HC have any statistics about how many Canadian psychiatrists specialize in eating disorders, and any statistics or information about what succession planning is in place to replace those who specialize in these disorders, broken down by province and territory; (f) do the CIHR and HC have any statistics about what eating disorders training programs are available for health professionals, and any statistics or information on what succession planning is in place to replace those who serve Canadians with eating disorders, broken down by province and territory; (g) do the CIHR and HC have any statistics about what long-term, publicly-funded residential care facilities are available, (i) the average wait time for treatment by such a facility, (ii) how many Canadians are forced to leave the country for treatment, (iii) the average cost to the family for out-of-country treatment, (iv) the cost to the health care system if the province or territory reimburses families for out-of-country treatment; (h) do the CIHR ...

(Return tabled) Question No. 199 Ms. Kirsty Duncan: With regard to the development and operation of the Canadian Multiple Sclerosis Monitoring System (CMSMS) announced in March 2011: (a) what are the government's baseline assumptions for the CMSMS, (i) how many Canadians live with MS according to the government’s source, (ii) what is the government's source; (b) what have been the challenges in developing the system between March 2011 and today, (i) how has each challenge been overcome, (ii) what are the achievements to date, (iii) what milestones has the government planned between December 2013 and December 2015 and by what dates; (c) ...[+++] what is the cost of developing the system, broken down by costs to date; (d) how much money did the Canadian Institutes for Health Research (CIHR) contribute to the development of the CMSMS, (i) were there any other partners involved in the development of the system, (ii) if so, who are they, (iii) what has each contributed; (e) who was involved in the design and development of the CMSMS, (i) from what departments/institutions were they, (ii) were potential conflicts of interest declared and, if so, how; (f) what health information does the CMSMS track, specifically, with regard to (i) chronic cerebrospinal venous insufficiency (CCSVI), (ii) impacts of CCSVI treatment, including but not limited to use of the following scales, Expanded Disability Status Scale, Modified Fatigue Impact Scale, Multiple Sclerosis Impact Scale, and Multiple Sclerosis Quality of Life Inventory, (iii) pharmaceutical treatments for MS, (vi) adverse drug reactions by MS drug; (g) who is/was overseeing pilot testing, (i) who is/was responsible for ensuring that patient information is/was protected, (ii) who is/was responsible for the integrity of the results; (h) were ethical reviews for pilot testing necessary and, if so, on what date did each pilot site pass ethical review; (i) when is pilot testing expected to/did it take place and at which MS clinics ...

In this context, appropriate consideration should be given to the reporting of results, particularly negative results, so that patients are not unnecessarily exposed to unsafe/ineffective treatments.

(Return tabled) Question No. 1169 Hon. Irwin Cotler: With regard to C-54, An Act to amend the Criminal Code and the National Defence Act (mental disorder): (a) in developing this legislation, on what (i) studies, (ii) case law, (iii) doctrinal sources did the government rely; (b) what statistics does the government track with respect to people found not criminally responsible (NCR) on account of mental disorder; (c) for each of the last ten years, broken down by province and territory and by type of offence, (i) how many people have been found NCR, (ii) which people found NCR have been released without conditions, (iii) which people fo ...[+++]und NCR have been released with conditions, (iv) how long has each person found NCR spent in treatment prior to release, (v) which people found NCR and released have been convicted of a subsequent offence, (vi) what was the nature of the subsequent offence, (vii) which people found NCR and released have been found NCR of a subsequent offence, (viii) what was the nature of the subsequent offence; (d) for each of the last ten years, what was the recidivism rate for all federal offenders; (e) broken down by province and territory, (i) which treatment facilities accept people found NCR, (ii) which of these facilities are privately owned, (iii) what is the capacity of each facility, (iv) how many people are currently housed in each facility; (f) what analysis has the government performed to determine whether this legislation will result in a need for increased capacity in these facilities; (g) what are the conclusions of this analysis; (h) what steps is the government taking to ensure adequate capacity in these facilities; (i) what funds are currently designated for (i) the construction of new facilities to house people found NCR, (ii) the expansion of existing such facilities; (j) what government programs exist to fund any such facilities that are privately owned; (k) what funds have been allocated to any such programs for each o ...